Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
Open Access
- 23 July 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 326 (11), 1063-1065
- https://doi.org/10.1001/jama.2021.12339
Abstract
Studies have reported low seroconversion rates (58% after the second dose) in solid organ transplant recipients who received a messenger RNA (mRNA) SARS-CoV-2 vaccine.1,2 Based on this evidence, the French National Authority for Health issued a recommendation in April 2021 to administer a third vaccine dose in immunosuppressed patients who did not respond after 2 doses. We examined the antibody responses of kidney transplant recipients who did not respond to 2 doses and received a third dose (100 μg) of the mRNA-1273 vaccine (Moderna).Keywords
This publication has 6 references indexed in Scilit:
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesAnnals of Internal Medicine, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsThe New England Journal of Medicine, 2021
- Occurrence of severe COVID-19 in vaccinated transplant patientsKidney International, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccineThe Lancet, 2021